文献速递皮肤肿瘤

皮肤镜标准诊断原位黑色素瘤的准确性

Accuracy of Dermoscopic Criteria for the Diagnosis of Melanoma In Situ.
PubMed 文献 · JAMA Dermatol · 2018-01-01

这项回顾性诊断准确性研究在3个中心纳入1285例组织病理诊断为原位黑色素瘤或其他平坦色素性皮肤肿瘤的患者,评估预设皮肤镜标准的诊断准确性发现,原位黑色素瘤最常见的皮肤镜标准为消退、非典型色素网络和不规则点/球,多因素分析显示非典型色素网络、消退、不规则深色色素区、显著皮纹和成角线条为原位黑色素瘤的主要阳性皮肤镜指标。

要点

  • 原位黑色素瘤最常见的皮肤镜标准为消退(92.9%)、非典型色素网络(85.5%)和不规则点/球(50.2%)。
  • 多因素分析显示非典型色素网络、消退、不规则深色色素区、显著皮纹和成角线条为原位黑色素瘤的主要阳性指标。
  • 仅与切除痣比较时,不规则深色色素区和显著皮纹仍为原位黑色素瘤的有力指标。

核心结论

  • 临床医生在诊断原位黑色素瘤时应考虑上述皮肤镜指标。

研究设计与样本

  • 在3个皮肤癌诊断与管理专科中心进行的回顾性诊断准确性研究,共纳入1285例组织病理诊断为原位黑色素瘤或其他平坦色素性皮肤肿瘤(经组织病理诊断或随访至少1年)的患者。
  • 由3名独立研究者评估预设皮肤镜标准的存在,评估者对临床皮肤镜和组织病理诊断设盲。

主要发现

  • 1285例患者中642例(50%)为男性,平均年龄45.9岁(范围9-91岁)。
  • 1285个病灶中,原位黑色素瘤325个(25.3%);痣574个(44.7%,其中切除312个[24.3%],未切除262个[20.4%]);脂溢性角化病、日光性黑子或扁平苔藓样角化病67个(5.2%);色素性浅表基底细胞癌91个(7.1%);色素性上皮内癌26个(2.0%);Reed痣100个(7.8%);Breslow厚度小于0.75 mm的浸润性黑色素瘤102个(7.9%)。
  • 原位黑色素瘤最常见的皮肤镜标准为消退(302个[92.9%])、非典型色素网络(278个[85.5%])和不规则点/球(163个[50.2%])。
  • 多因素分析显示5个主要阳性皮肤镜指标:非典型色素网络(3.7倍;95%CI,2.5-5.4)、消退(4.7倍;95%CI,2.8-8.1)、不规则深色色素区(5.4倍;95%CI,3.7-8.0)、显著皮纹(3.4倍;95%CI,1.9-6.1)和成角线条(2.2倍;95%CI,1.2-4.1)。
  • 仅与切除痣比较时,其中2个标准仍为原位黑色素瘤的有力指标:不规则深色色素区(4.3倍;95%CI,2.7-6.8)和显著皮纹(2.7倍;95%CI,1.3-5.7)。

临床怎么用

  • 作者认为,临床医生在诊断原位黑色素瘤时应考虑上述皮肤镜指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The accuracy of melanoma-specific dermoscopic criteria has been tested mainly in studies including invasive tumors. Scarce evidence exists on the usefulness of these criteria for the diagnosis of melanoma in situ (MIS). OBJECTIVE: To investigate the diagnostic accuracy of dermoscopic criteria for the diagnosis of MIS. DESIGN, SETTING, AND PARTICIPANTS: A diagnostic accuracy study with retrospective patient enrollment was conducted in 3 centers specializing in skin cancer diagnosis and management. A total of 1285 individuals with histopathologically diagnosed MIS or other flat, pigmented skin tumors that were histopathologically diagnosed or monitored for at least 1 year were included. Dermoscopic images of MIS and other flat, pigmented skin tumors were evaluated by 3 independent investigators for the presence of predefined criteria. Evaluators were blinded to the clinic dermoscopic and histopathologic diagnosis. MAIN OUTCOMES AND MEASURES: Frequencies of dermoscopic criteria per diagnosis were calculated. Crude odds ratios, adjusted odds ratios, and corresponding 95% CIs were calculated by univariate and multivariate logistic regression, respectively. RESULTS: A total of 1285 patients were included in the study (642 [50%] male); mean age was 45.9 years (range, 9-91 years). Of a total of 1285 lesions obtained from these patients, 325 (25.3%) were MIS; 574 (44.7%) were nevi (312 [24.3%] excised and 262 [20.4%] not excised); 67 (5.2%) were seborrheic keratoses, solar lentigines, or lichen planus-like keratoses; 91 (7.1%) were pigmented superficial basal cell carcinomas; 26 (2.0%) were pigmented intraepithelial carcinomas; 100 (7.8%) were Reed nevi; and 102 (7.9%) were invasive melanomas with a Breslow thickness less than 0.75 mm. The most frequent dermoscopic criteria for MIS were regression (302 [92.9%]), atypical network (278 [85.5%]), and irregular dots and/or globules (163 [50.2%]). The multivariate analysis revealed 5 main positive dermoscopic indicators of MIS: atypical network (3.7-fold; 95% CI, 2.5-5.4), regression (4.7-fold; 95% CI, 2.8-8.1), irregular hyperpigmented areas (5.4-fold; 95% CI, 3.7-8.0), prominent skin markings (3.4-fold; 95% CI, 1.9-6.1), and angulated lines (2.2-fold; 95% CI, 1.2-4.1). When compared only with excised nevi, 2 of these criteria remained potent MIS indicators, namely, irregular hyperpigmented areas (4.3-fold; 95% CI, 2.7-6.8) and prominent skin markings (2.7-fold; 95% CI, 1.3-5.7). CONCLUSIONS AND RELEVANCE: Clinicians should take into consideration the aforementioned dermoscopic indicators for the diagnosis of MIS.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Lallas A, Longo C, Manfredini M, et al. Accuracy of Dermoscopic Criteria for the Diagnosis of Melanoma In Situ. JAMA Dermatol. 2018. PMID: 29466542. doi:10.1001/jamadermatol.2017.6447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。